40
Participants
Start Date
January 13, 2020
Primary Completion Date
June 1, 2025
Study Completion Date
December 1, 2025
Pembrolizumab
predetermined dose, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
PEMETREXED
administered per standard practice, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
CARBOPLATIN
administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
PACLITAXEL
administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
InVision
Plasma draw for clinical test performed at C1D1 and C2D1; plasma draw for research testing performed at other timepoints per protocol.
Brigham and Women's Hospital, Boston
Dana Farber Cancer Institute, Boston
Boston Medical Center, Boston
Dana-Farber at Steward St. Elizabeth's Medical Center, Brighton
Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in clinical affiliation with South Shore Hospital, South Weymouth
Collaborators (1)
Inivata
INDUSTRY
Julia K. Rotow, MD
OTHER